IL129416A0 - New heterocyclylmethyl-substituted pyrazol derivatives - Google Patents
New heterocyclylmethyl-substituted pyrazol derivativesInfo
- Publication number
- IL129416A0 IL129416A0 IL12941697A IL12941697A IL129416A0 IL 129416 A0 IL129416 A0 IL 129416A0 IL 12941697 A IL12941697 A IL 12941697A IL 12941697 A IL12941697 A IL 12941697A IL 129416 A0 IL129416 A0 IL 129416A0
- Authority
- IL
- Israel
- Prior art keywords
- alkyl
- substituted
- alkoxy
- formula
- phenyl
- Prior art date
Links
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- -1 (each with up to 6C) Chemical group 0.000 abstract 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 150000003217 pyrazoles Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL14219001A IL142190A0 (en) | 1996-10-14 | 2001-03-22 | New 3-heterocyclmethyl-substituted pyrazol derivatives, processes for their preparation and their use as medicaments |
| IL14219101A IL142191A0 (en) | 1996-10-14 | 2001-03-22 | New 1-benzyl-3-(substituted heteroaryl)-fused pyrazol derivatives, processes for their preparation and their use as medicaments |
| IL14218901A IL142189A0 (en) | 1996-10-14 | 2001-03-22 | New heterocyclylmethyl-substituted pyrazol derivatives, processes for their preparation and their use as medicaments |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1996142322 DE19642322A1 (de) | 1996-10-14 | 1996-10-14 | Neue 3-Heterocyclyl-substituierte Pyrazolderivate |
| DE1996142323 DE19642323A1 (de) | 1996-10-14 | 1996-10-14 | Neue 1-Benzyl-3-(substituierte heteroaryl)-kondensierte Pyrazol-Derivate |
| DE1996142319 DE19642319A1 (de) | 1996-10-14 | 1996-10-14 | Neue Heterocyclylmethyl-substituierte Pyrazolderivate |
| DE1996142320 DE19642320A1 (de) | 1996-10-14 | 1996-10-14 | Neue 1-Methyl-heterocyclyl-substituierte Pyrazole |
| PCT/EP1997/005432 WO1998016507A2 (de) | 1996-10-14 | 1997-10-02 | Neue heterocyclylmethyl-substituierte pyrazolederivate und ihre verwendung in des behandlung von herz-kreislauf-erkrankungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL129416A0 true IL129416A0 (en) | 2000-02-17 |
Family
ID=27438459
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12941697A IL129416A0 (en) | 1996-10-14 | 1997-10-02 | New heterocyclylmethyl-substituted pyrazol derivatives |
| IL14219001A IL142190A0 (en) | 1996-10-14 | 2001-03-22 | New 3-heterocyclmethyl-substituted pyrazol derivatives, processes for their preparation and their use as medicaments |
| IL14218901A IL142189A0 (en) | 1996-10-14 | 2001-03-22 | New heterocyclylmethyl-substituted pyrazol derivatives, processes for their preparation and their use as medicaments |
| IL14219101A IL142191A0 (en) | 1996-10-14 | 2001-03-22 | New 1-benzyl-3-(substituted heteroaryl)-fused pyrazol derivatives, processes for their preparation and their use as medicaments |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14219001A IL142190A0 (en) | 1996-10-14 | 2001-03-22 | New 3-heterocyclmethyl-substituted pyrazol derivatives, processes for their preparation and their use as medicaments |
| IL14218901A IL142189A0 (en) | 1996-10-14 | 2001-03-22 | New heterocyclylmethyl-substituted pyrazol derivatives, processes for their preparation and their use as medicaments |
| IL14219101A IL142191A0 (en) | 1996-10-14 | 2001-03-22 | New 1-benzyl-3-(substituted heteroaryl)-fused pyrazol derivatives, processes for their preparation and their use as medicaments |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US6166027A (enExample) |
| EP (2) | EP0934311B1 (enExample) |
| JP (1) | JP4351298B2 (enExample) |
| AT (1) | ATE431347T1 (enExample) |
| AU (1) | AU736303B2 (enExample) |
| BR (1) | BR9712523A (enExample) |
| CA (1) | CA2268394C (enExample) |
| CZ (1) | CZ130999A3 (enExample) |
| DE (1) | DE59713007D1 (enExample) |
| EE (1) | EE9900151A (enExample) |
| ES (1) | ES2325045T3 (enExample) |
| HU (1) | HUP0001115A3 (enExample) |
| ID (1) | ID22176A (enExample) |
| IL (4) | IL129416A0 (enExample) |
| NO (1) | NO991732L (enExample) |
| NZ (1) | NZ335092A (enExample) |
| PL (1) | PL332871A1 (enExample) |
| SK (1) | SK48799A3 (enExample) |
| TR (1) | TR199901174T2 (enExample) |
| TW (1) | TW504513B (enExample) |
| WO (1) | WO1998016507A2 (enExample) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19744026A1 (de) * | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| US6451805B1 (en) * | 1997-11-14 | 2002-09-17 | Bayer Aktiengesellschaft | Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) * | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| GB9824310D0 (en) * | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| DE19853278A1 (de) | 1998-11-19 | 2000-05-25 | Aventis Pharma Gmbh | Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE19904710A1 (de) | 1999-02-05 | 2000-08-10 | Aventis Pharma Gmbh | Substituierte 4-Amino-2-aryl-tetrahydrochinazoline, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943636A1 (de) * | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10054278A1 (de) * | 2000-11-02 | 2002-05-08 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Osteoporose |
| WO2002042299A1 (de) | 2000-11-22 | 2002-05-30 | Bayer Aktiengesellschaft | Neue lactam-substituierte pyrazolopyridinderivate |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10057754A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Sulfonamid-substituierte Pyrazolopyridinderivate |
| DE10057751A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Carbamat-substituierte Pyrazolopyridinderivate |
| DE10109861A1 (de) | 2001-03-01 | 2002-09-05 | Bayer Ag | Neuartige seitenkettenhalogenierte Aminodicarbonsäurederivate |
| DE10109858A1 (de) | 2001-03-01 | 2002-09-05 | Bayer Ag | Neuartige halogensubstituierte Aminodicarbonsäurederivate |
| DE10122894A1 (de) | 2001-05-11 | 2002-11-14 | Bayer Ag | Neue Sulfonat-substituierte Pyrazolopyridinderivate |
| TWI264304B (en) | 2002-01-25 | 2006-10-21 | Yung Shin Pharm Ind Co Ltd | Methods of treating sepsis |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| DE10244810A1 (de) | 2002-09-26 | 2004-04-08 | Bayer Ag | Neue Morpholin-überbrückte Indazolderivate |
| US20050096370A1 (en) * | 2003-04-07 | 2005-05-05 | Bizbiotech Co., Ltd. | Method for inhibiting tumor angiogenesis and tumor growth |
| AU2004275694B2 (en) * | 2003-06-30 | 2008-03-06 | Bizbiotech Co., Ltd. | Compounds, compositions and methods |
| US6984652B2 (en) * | 2003-09-05 | 2006-01-10 | Warner-Lambert Company Llc | Gyrase inhibitors |
| WO2005077005A2 (en) * | 2004-02-04 | 2005-08-25 | The General Hospital Corporation | Enhancing the effectiveness of an inhaled therapeutic gas |
| AU2005308523B2 (en) * | 2004-11-29 | 2010-01-07 | Warner-Lambert Company Llc | Therapeutic pyrazolo[3,4-b] pyridines and indazoles |
| DE102005050497A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Difluorphenol-Derivate und ihre Verwendung |
| DE102005050377A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Heterocyclische Verbindungen und ihre Verwendung |
| DE102005050376A1 (de) | 2005-10-21 | 2007-05-31 | Bayer Healthcare Ag | Dicarbonsäure-Derivate und ihre Verwendung |
| DE102005050498A1 (de) | 2005-10-21 | 2007-06-06 | Bayer Healthcare Aktiengesellschaft | Cyclopropylessigsäure-Derivate und ihre Verwendung |
| DE102005050375A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Tetrazol-Derivate und ihre Verwendung |
| WO2007065010A2 (en) * | 2005-12-02 | 2007-06-07 | Hif Bio, Inc. | Anti-angiogenesis compounds |
| DE102006020327A1 (de) * | 2006-04-27 | 2007-12-27 | Bayer Healthcare Ag | Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung |
| DE102006021733A1 (de) * | 2006-05-09 | 2007-11-22 | Bayer Healthcare Ag | 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung |
| DE102006043443A1 (de) | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
| DE102006054757A1 (de) * | 2006-11-21 | 2008-05-29 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
| US20110014255A1 (en) * | 2006-12-22 | 2011-01-20 | Marc Balastre | Phytosanitary formulation generating nanoparticles, method for preparing nanoparticles and use thereof |
| DE102007015035A1 (de) | 2007-03-29 | 2008-10-02 | Bayer Healthcare Ag | Substituierte Dibenzoesäure-Derivate und ihre Verwendung |
| DE102007015034A1 (de) | 2007-03-29 | 2008-10-02 | Bayer Healthcare Ag | Lactam-substituierte Dicarbonsäuren und ihre Verwendung |
| US20080252028A1 (en) * | 2007-04-16 | 2008-10-16 | Ming-Tai Huang | Shock absorbing device for toy stroller |
| DE102007026392A1 (de) | 2007-06-06 | 2008-12-11 | Bayer Healthcare Ag | Lösungen für die Perfusion und Konservierung von Organen und Geweben |
| DE102007028320A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DE102007028407A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DE102007028319A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DE102007028406A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
| EP2138178A1 (en) | 2008-06-28 | 2009-12-30 | Bayer Schering Pharma Aktiengesellschaft | Oxazolidninones for the treatment fo chronic obstructive pulmonary disease (COPD) and/or asthma |
| AU2009322836B2 (en) * | 2008-11-25 | 2013-04-04 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| DE102008063992A1 (de) | 2008-12-19 | 2010-09-02 | Lerner, Zinoviy, Dipl.-Ing. | Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung |
| UY33041A (es) | 2009-11-27 | 2011-06-30 | Bayer Schering Pharma Aktienegesellschaft | Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico |
| KR101861981B1 (ko) | 2009-11-27 | 2018-05-28 | 아드베리오 파마 게엠베하 | 제약상 물질로서 사용하기 위한 메틸-(4,6-디아미노-2-(1-(2-플루오로벤질)-1ｈ-피라졸로(3,4-ｂ)피리디노-3-일)피리미디노-5-일)메틸카르바메이트의 제조 방법 및 그의 정제 |
| US9284301B2 (en) | 2010-03-25 | 2016-03-15 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| CA2799154A1 (en) | 2010-05-12 | 2011-11-17 | Abbvie Inc. | Indazole inhibitors of kinase |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| EA023254B1 (ru) | 2010-05-27 | 2016-05-31 | Мерк Шарп Энд Домэ Корп. | Активаторы растворимой гуанилатциклазы |
| CN103313976B (zh) * | 2010-06-30 | 2016-11-23 | 铁木医药有限公司 | sGC刺激物 |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| EP2632551B1 (en) | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| DE102012200354A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Heteroaryl-substituierte Pyrazolopyridine und ihre Verwendung |
| EP2729476B1 (de) * | 2011-07-06 | 2017-08-23 | Bayer Intellectual Property GmbH | Heteroaryl-substituierte pyrazolopyridine und ihre verwendung als stimulatoren der löslichen guanylatcyclase |
| DE102011078715A1 (de) | 2011-07-06 | 2013-01-10 | Bayer Pharma AG | Heteroaryl-substituierte Pyrazolopyridine und ihre Verwendung |
| UA111754C2 (uk) | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| LT3421470T (lt) | 2011-11-25 | 2021-04-26 | Adverio Pharma Gmbh | Pakeistieji 5-fluor-1h-pirazolopiridinai kristalų pavidale |
| DE102012200349A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung |
| DE102012200360A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte Triazine und ihre Verwendung |
| ES2644781T3 (es) | 2012-03-06 | 2017-11-30 | Bayer Intellectual Property Gmbh | Azabiciclos sustituidos y su uso |
| SG10201609322QA (en) | 2012-05-10 | 2017-01-27 | Bayer Pharma AG | Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof |
| US9738610B2 (en) | 2012-09-24 | 2017-08-22 | Whitehead Institute For Biomedical Research | Indazole derivatives and uses thereof |
| AU2014220801A1 (en) | 2013-02-21 | 2015-09-10 | Adverio Pharma Gmbh | Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate |
| MX2016000258A (es) | 2013-07-10 | 2016-04-28 | Bayer Pharma AG | Bencil-1h-pirazolo[3,4-b]piridinas y su uso. |
| US20160324856A1 (en) | 2014-01-13 | 2016-11-10 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of neuromuscular disorders |
| PE20170697A1 (es) | 2014-09-19 | 2017-06-24 | Bayer Pharma AG | Indazoles sustituidos con benzilo como inhibidores de bub1 |
| WO2016177660A1 (en) | 2015-05-06 | 2016-11-10 | Bayer Pharma Aktiengesellschaft | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc) |
| SI3325013T2 (sl) | 2015-07-23 | 2023-11-30 | Bayer Pharma Aktiengesellschaft | Stimulatorji/aktivatorji topne gvanilat ciklaze v kombinaciji z zaviralcem NEP in/ali antagonistom angiotenzina II in njihova uporaba |
| CA3006764A1 (en) | 2015-12-14 | 2017-06-22 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of gastrointestinal sphincter dysfunction |
| EP3525779B1 (de) | 2016-10-11 | 2024-06-05 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend den sgc stimulator vericuguat und den mineralcorticoid-rezeptor-antagonist finerenone |
| EP3525778A1 (de) | 2016-10-11 | 2019-08-21 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten |
| US20190381039A1 (en) | 2016-12-13 | 2019-12-19 | Cyclerion Therapeutics, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS |
| EP3609883B1 (en) | 2017-04-11 | 2022-06-29 | Sunshine Lake Pharma Co., Ltd. | Fluorine-substituted indazole compounds and uses thereof |
| MX2020012230A (es) | 2018-05-15 | 2021-01-29 | Bayer Ag | Uso de benzamidas sustituidas con 1,3-tiazol-2-ilo para el tratamiento de enfermedades asociadas con la sensibilizacion de las fibras nerviosas. |
| KR20210031931A (ko) | 2018-07-11 | 2021-03-23 | 사이클리온 테라퓨틱스, 인크. | 미토콘드리아 장애의 치료를 위한 sGC 자극제의 용도 |
| WO2020164008A1 (en) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Process for the preparation of porous microparticles |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3994890A (en) * | 1974-01-31 | 1976-11-30 | Chugai Seiyaku Kabushiki Kaisha | 1-Aminoalkyl, 3-phenyl indazoles |
| HU198036B (en) * | 1983-08-22 | 1989-07-28 | Hoechst Roussel Pharma | Process for production of derivatives of 3-piperidil-/1h/-indasole and medical preparatives containing them |
| ZW19786A1 (en) * | 1985-10-17 | 1988-05-18 | Hoffmann La Roche | Heterocyclic compounds |
| JP2928079B2 (ja) * | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途 |
| CN1039536C (zh) * | 1994-02-28 | 1998-08-19 | 永信药品工业股份有限公司 | 1,3取代缩合吡唑类化合物及其应用和制备方法 |
| ZA951822B (en) * | 1994-12-23 | 1996-09-26 | Glaxo Group Ltd | Chemical compounds |
-
1997
- 1997-10-02 EP EP97912102A patent/EP0934311B1/de not_active Expired - Lifetime
- 1997-10-02 JP JP51797198A patent/JP4351298B2/ja not_active Expired - Fee Related
- 1997-10-02 AU AU49430/97A patent/AU736303B2/en not_active Ceased
- 1997-10-02 EP EP05022495A patent/EP1686127A1/de not_active Withdrawn
- 1997-10-02 US US09/284,172 patent/US6166027A/en not_active Expired - Fee Related
- 1997-10-02 ID IDW990188A patent/ID22176A/id unknown
- 1997-10-02 PL PL97332871A patent/PL332871A1/xx unknown
- 1997-10-02 EE EEP199900151A patent/EE9900151A/xx unknown
- 1997-10-02 SK SK487-99A patent/SK48799A3/sk unknown
- 1997-10-02 HU HU0001115A patent/HUP0001115A3/hu unknown
- 1997-10-02 ES ES97912102T patent/ES2325045T3/es not_active Expired - Lifetime
- 1997-10-02 CA CA002268394A patent/CA2268394C/en not_active Expired - Fee Related
- 1997-10-02 WO PCT/EP1997/005432 patent/WO1998016507A2/de not_active Ceased
- 1997-10-02 NZ NZ335092A patent/NZ335092A/en unknown
- 1997-10-02 BR BR9712523-7A patent/BR9712523A/pt not_active IP Right Cessation
- 1997-10-02 DE DE59713007T patent/DE59713007D1/de not_active Expired - Lifetime
- 1997-10-02 AT AT97912102T patent/ATE431347T1/de not_active IP Right Cessation
- 1997-10-02 IL IL12941697A patent/IL129416A0/xx unknown
- 1997-10-02 CZ CZ991309A patent/CZ130999A3/cs unknown
- 1997-10-02 TR TR1999/01174T patent/TR199901174T2/xx unknown
- 1997-10-14 TW TW086115204A patent/TW504513B/zh active
-
1999
- 1999-04-13 NO NO991732A patent/NO991732L/no not_active Application Discontinuation
-
2000
- 2000-08-23 US US09/644,305 patent/US6462068B1/en not_active Expired - Fee Related
- 2000-08-23 US US09/644,179 patent/US6387940B1/en not_active Expired - Fee Related
- 2000-08-25 US US09/645,834 patent/US6410740B1/en not_active Expired - Fee Related
- 2000-08-25 US US09/648,082 patent/US6414009B1/en not_active Expired - Fee Related
-
2001
- 2001-03-22 IL IL14219001A patent/IL142190A0/xx unknown
- 2001-03-22 IL IL14218901A patent/IL142189A0/xx unknown
- 2001-03-22 IL IL14219101A patent/IL142191A0/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL129416A0 (en) | New heterocyclylmethyl-substituted pyrazol derivatives | |
| ATE167475T1 (de) | N-substituierte heterozyklische derivate, verfahren zu deren herstellung, diese enthaltende zusammensetzungen | |
| NO304946B1 (no) | Xantinderivat samt dets anvendelse | |
| AU2001284658A1 (en) | Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists | |
| PT89912A (pt) | Processo para a preparacao de derivados de tiazolidinodiona hipoglicemicos | |
| EP0304493A4 (en) | HYDROXYSTYRENE DERIVATIVES. | |
| ES2161594A1 (es) | Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| NZ332481A (en) | 5-[2,4-diaminopyrimidinylmethyl]phenyl substituted propanone (or propenone) isoquinoline derivatives and medicaments | |
| MXPA03001558A (es) | Agonistas del receptor activado del proliferador de peroxisoma. | |
| BR9802212A (pt) | Compostos cromeno um processo para sua preparação e composições farmacêuticas contendo os mesmos | |
| FI923540A0 (fi) | Arylalkylaminer och -amider med antikonvulsiva och nervskyddande egenskaper. | |
| DE69621877D1 (de) | 4-Indolylpiperazinyl-Derivate | |
| FI940306A0 (fi) | Menetelmä kiraalisten tiatsolidiini-2,4-dionijohdannaisten synteesissä tarvittavien välituotteiden valmistamiseksi | |
| AU2001232032A1 (en) | Benzooxazole derivatives as tnf and pde iv inhibitors | |
| EP1886999A8 (en) | Bicyclic heteroaromatic compounds | |
| DE60216610D1 (de) | Verwendung von kondensierten Pyrazolverbindungen für die Herstellung eines Arzneimittels zur Behandlung von Bluthochdruck | |
| EP0773019A4 (en) | MEDICINE AGAINST HYPERLIPEMIA | |
| WO2002096886A8 (en) | Pyrimidine derivatives | |
| NO963374D0 (no) | Substituerte 4H-pyraner | |
| IE37961B1 (en) | 6-(alpha-(amidino-and imidoylaminoalkanoylamino)penicillanic acids | |
| GB1360759A (en) | 3-oxy-iminomethyl cephalosporin compounds | |
| JP2005514361A5 (enExample) | ||
| TH17791A (th) | สารต่อต้านเชื้อราชนิดอะโซลที่ละลายได้ในน้ำ |